CD8A and neoplasm: More importantly, traditional T cell therapy is often limited in effect due to exhaustion caused by the tumor microenvironment and poor antigen recognition, while CAR engineering enables CD4 + and CD8 + T cell subsets to work synergistically to completely eliminate tumors.